Tamanho do Mercado de Testes Point-Of-Care (POCT) na América do Norte, Tendências, Relatório de Crescimento 2033

North America Point Care Testing Poct Market

Tamanho do mercado em biliões de dólares

CAGR : 9.60 %

USD 25.20 Billion USD 52.47 Billion 2025 2033

Período de previsão	2026 –2033
Tamanho do mercado (ano base )	USD 25.20 Billion
Tamanho do mercado ( Ano de previsão)	USD 52.47 Billion
CAGR	9.60 %
Principais participantes do mercado	Abbott Point of Care Inc. Sinocare Inc. F. Hoffmann-La Roche Ltd Danaher Corporation Hologic Inc.

Mercado de Testes no Local de Atendimento (POCT) na América do Norte, por Tipo de Produto (Produtos para Monitoramento de Glicose, Produtos para Testes de Doenças Infecciosas, Produtos para Monitoramento Cardiometabólico, Produtos para Testes de Gravidez e Fertilidade, Produtos para Testes Hematológicos, Produtos para Monitoramento da Coagulação, Produtos para Testes de Drogas de Abuso (DOA), Produtos para Testes de Urina, Produtos para Testes de Colesterol, Produtos para Testes de Marcadores Tumorais/Cancerígenos, Produtos para Testes de Oculto Fecal e Outros), por Plataforma (Ensaios de Fluxo Lateral/Testes de Imunocromatografia, Imunoensaios, Tiras de Imersão, Diagnóstico Molecular, Ensaios de Química Clínica, Microfluídica, Hematologia e Outros), por Aplicação (Glicose no Sangue, Doenças Infecciosas, Monitoramento de Sinais Vitais, Monitoramento Cardíaco, Coagulação, Hematologia, Monitoramento Não Invasivo de SpO2, Transfusão de Sangue, Monitoramento Não Invasivo de PCO2, Análise de Sangue Total e Outros). Modalidade de prescrição (testes com prescrição e testes de venda livre), por usuário final (hospitais, assistência domiciliar, clínicas, laboratórios, centros de diagnóstico, laboratórios de patologia, centros cirúrgicos ambulatoriais, centros de cuidados para idosos e outros), por canal de distribuição (licitação direta, vendas no varejo, vendas online e outros) e por país (EUA, Canadá e México) - Tendências e previsões do setor até 2033.

Tamanho do mercado de testes no local de atendimento (POCT) na América do Norte

O mercado de testes Point-Of-Care (POCT) na América do Norte foi avaliado em US$ 25,20 bilhões em 2025 e deverá atingir US$ 52,47 bilhões até 2033 , com uma taxa de crescimento anual composta (CAGR) de 9,6% durante o período de previsão.
O crescimento do mercado de testes no local de atendimento (POCT) na América do Norte é impulsionado principalmente pela crescente demanda por soluções de diagnóstico rápido que permitam a tomada de decisões clínicas imediatas e reduzam a dependência de testes laboratoriais centralizados. Os dispositivos POCT possibilitam tempos de resposta mais rápidos, detecção precoce de doenças e melhores resultados para os pacientes, o que é fundamental em atendimento de emergência, assistência médica remota e monitoramento domiciliar.
A crescente prevalência de doenças crônicas, como diabetes, distúrbios cardiovasculares, doenças infecciosas e doenças respiratórias, está aumentando significativamente a adoção de dispositivos POCT (Point-of-Care Testing) para monitoramento e gerenciamento em tempo real. Além disso, os avanços em tecnologias de diagnóstico, microfluídica, biossensores e plataformas de saúde conectadas estão aprimorando a precisão, a portabilidade e as capacidades de integração de dados, impulsionando o crescimento do mercado.

Análise do mercado de testes no local de atendimento (POCT) na América do Norte

O mercado de testes no local de atendimento (POCT) na América do Norte é um segmento em rápida expansão na indústria de diagnóstico, oferecendo resultados imediatos diretamente no local de atendimento ao paciente, como clínicas, hospitais, ambulâncias e domicílios. Os dispositivos POCT proporcionam triagem e monitoramento rápidos para condições como diabetes, doenças infecciosas, gravidez, marcadores cardíacos, desequilíbrio eletrolítico e parâmetros de coagulação, permitindo maior eficiência clínica e redução da sobrecarga do sistema de saúde.
A crescente demanda por tecnologias de diagnóstico portáteis e fáceis de usar é impulsionada principalmente pelo aumento da prevalência de doenças crônicas, pelas necessidades de atendimento de emergência e pela expansão do monitoramento domiciliar de pacientes. Além disso, a integração de plataformas de saúde digital, diagnósticos baseados em smartphones, detecção habilitada por IA e conectividade sem fio oferece suporte a uma melhor rastreabilidade de dados e ao gerenciamento remoto de pacientes, impulsionando ainda mais o crescimento do mercado.
Prevê-se que os EUA dominem o mercado de testes Point-Of-Care (POCT) na América do Norte, com a maior participação de receita, em torno de 83,12% em 2026, impulsionados pela forte presença de importantes players do mercado, altos gastos com saúde, infraestrutura médica avançada e crescente adoção de tecnologias de diagnóstico inovadoras em hospitais e ambientes de atendimento domiciliar.
O segmento de Produtos para Monitoramento de Glicose deverá dominar o mercado de POCT (Point-of-Care Testing) na América do Norte, com uma participação significativa de mais de 38,86% em 2026, impulsionado pelo aumento da população diabética, pela preferência por dispositivos de monitoramento em tempo real e pelo uso crescente de glicosímetros portáteis e ferramentas de monitoramento contínuo de glicose entre pacientes em cuidados domiciliares.

Escopo do relatório e segmentação do mercado de testes no local de atendimento (POCT) na América do Norte

Atributos	Principais informações sobre o mercado de testes no local de atendimento (POCT) na América do Norte
Segmentos abrangidos	Por tipo de produto : Produtos para monitoramento de glicose, Produtos para testes de doenças infecciosas, Produtos para monitoramento cardiometabólico, Produtos para testes de gravidez e fertilidade, Produtos para testes hematológicos, Produtos para monitoramento de coagulação, Produtos para testes de drogas de abuso (DOA), Produtos para testes de urina, Produtos para testes de colesterol, Produtos para testes de marcadores tumorais/cancerígenos, Produtos para testes de sangue oculto nas fezes e Outros. Por plataforma: Ensaios de fluxo lateral/Testes de imunocromatografia, Imunoensaios, Tiras reagentes, Diagnóstico molecular, Ensaios de química clínica, Microfluídica, Hematologia, Outros Por aplicação: Glicemia, Doenças infecciosas, Monitoramento de sinais vitais, Monitoramento cardíaco, Coagulação, Hematologia, Monitoramento não invasivo de SpO2, Transfusão de sangue, Monitoramento não invasivo de PCO2, Análise de sangue total, Outros Por modalidade de prescrição: testes com prescrição médica e testes de venda livre. Por usuário final: Hospitais, Assistência Domiciliar, Clínicas, Laboratórios, Centros de Diagnóstico, Laboratórios de Patologia, Centros de Cirurgia Ambulatorial, Centros de Cuidados para Idosos, Outros Por canal de distribuição: Licitação direta, Vendas no varejo, Vendas online e Outros.
Países abrangidos	América do Norte NÓS Canadá México
Principais participantes do mercado	Abbott Point of Care Inc. (EUA) Sinocare Inc. (China) F. Hoffmann-La Roche Ltda. (Suíça) Danaher Corporation (EUA) Hologic, Inc. (EUA) bioMérieux SA (França) Siemens Healthineers AG (Alemanha) Thermo Fisher Scientific Inc. (EUA) BD Veritor (Becton, Dickinson and Company) (EUA) Corporação QuidelOrtho (EUA) Bio-Rad Laboratories, Inc. (EUA) Werfen (Espanha) Sekisui Diagnostics (Japão) Trividia Health, Inc. (EUA) Nova Biomedical Corporation (EUA) Meridian Bioscience, Inc. (EUA) Pfizer Inc. (EUA) Shenzhen New Industry Biomedical Engineering Co., Ltd. (China) Corporação Sysmex (Japão) Wondfo (Guangzhou Wondfo Biotech Co., Ltd.) (China) QIAGEN NV (Alemanha) Abaxis, Inc. (EUA) Autobio Diagnostics Co., Ltd. (China) Getein Biotech, Inc. (China) Chembio Diagnostics, Inc. (EUA) EKF Diagnostics Holdings plc (Reino Unido) Trinity Biotech plc (Irlanda) Diagnóstico PTS (EUA) QuantuMDx Group Ltd. (Reino Unido) Binx Health (EUA) Xiamen Boson Biotech Co., Ltd. (China) Accubiotech Co., Ltd. (China) Sienco, Inc. (EUA) Corporação LambdaGen (EUA)
Oportunidades de mercado	Adoção crescente de soluções de monitoramento de pacientes em domicílio e remotamente Integração de Saúde Digital, IA e Plataformas de Diagnóstico Conectadas
Conjuntos de informações de dados de valor agregado	Além das informações sobre cenários de mercado, como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e principais players, os relatórios de mercado elaborados pela Data Bridge Market Research também incluem rastreador de inovação e análise estratégica, avanços tecnológicos, cenário de mudanças climáticas, análise da cadeia de suprimentos, análise da cadeia de valor, critérios de seleção de fornecedores, análise PESTLE, análise de Porter, análise de patentes, análise do ecossistema da indústria, cobertura de matérias-primas, tarifas e seu impacto no mercado, cobertura regulatória, comportamento de compra do consumidor, perspectiva da marca, detalhamento da análise de custos e estrutura regulatória.

Tendências do mercado de testes no local de atendimento (POCT) na América do Norte

“Avanços tecnológicos e expansão funcional por meio de P&D e integração digital ”

Uma tendência importante e em rápida ascensão no mercado de testes no local de atendimento (POCT) na América do Norte é o foco crescente em inovação, pesquisa e desenvolvimento (P&D) e tecnologias de diagnóstico avançadas, visando aprimorar a precisão, a velocidade, a portabilidade e a tomada de decisões em tempo real. Com a crescente demanda por testes descentralizados e centrados no paciente, provedores de saúde, empresas de diagnóstico e fabricantes de dispositivos médicos estão investindo fortemente em plataformas POCT de última geração que oferecem suporte a diagnósticos de precisão e conectividade aprimorada em diferentes ambientes de atendimento.
Empresas líderes como Abbott, Roche, Siemens Healthineers, Danaher e Thermo Fisher Scientific estão acelerando seus esforços de pesquisa para desenvolver dispositivos miniaturizados, tecnologias de laboratório em chip e sistemas de teste com inteligência artificial capazes de fornecer resultados com qualidade de laboratório no local da necessidade. Esses avanços tecnológicos também incluem o manuseio automatizado de amostras, a melhoria da sensibilidade dos biossensores e a capacidade de realizar testes multiplex, permitindo a detecção simultânea de múltiplos biomarcadores.
Na área de diagnóstico de doenças infecciosas, extensas iniciativas de P&D estão focadas na produção de soluções de testes moleculares rápidos, com alta precisão, menor tempo de resposta e adequadas para situações de emergência e surtos. Dispositivos de POCT (Point-of-Care Testing) projetados para influenza, COVID-19, infecções respiratórias, HIV e sepse estão sendo aprimorados com tecnologias de microfluídica e amplificação isotérmica, permitindo testes confiáveis fora de laboratórios centralizados.
Na gestão de doenças crônicas, a inovação no monitoramento da glicose, nos testes de biomarcadores cardíacos, nos testes de coagulação e na análise da função renal está apoiando o monitoramento contínuo e fornecendo dados em tempo real para intervenção clínica. As empresas estão integrando aplicativos móveis, relatórios baseados em nuvem e diagnósticos vestíveis para permitir o monitoramento domiciliar contínuo e a conectividade remota de telemedicina.
O mercado também está testemunhando uma expansão no diagnóstico personalizado, com soluções de POCT (Point-of-Care Testing) sendo desenvolvidas para apoiar a triagem em oncologia, fertilidade, distúrbios gastrointestinais e doenças metabólicas. Essas inovações visam possibilitar a detecção precoce, decisões terapêuticas mais rápidas e melhores resultados clínicos, especialmente em ambientes ambulatoriais e de atendimento domiciliar.
Além disso, a integração de dispositivos conectados, análise de dados digitais e interpretação orientada por IA está possibilitando ecossistemas de POCT mais inteligentes, que aprimoram a automação do fluxo de trabalho e reduzem erros humanos. Esses avanços estão transformando o POCT em uma ferramenta de diagnóstico multifuncional e inteligente, capaz de apoiar a medicina preventiva, a medicina de precisão e a gestão da saúde populacional.
Este ambiente em rápida evolução e impulsionado pela inovação está remodelando o mercado de POCT (Point-of-Care Testing), direcionando o setor para sistemas de diagnóstico portáteis, integrados e centrados no paciente. À medida que os sistemas de saúde da América do Norte priorizam a eficiência, a acessibilidade e a sustentabilidade, espera-se que a transformação digital impulsionada por P&D (Pesquisa e Desenvolvimento) desbloqueie novas aplicações e expanda a penetração de mercado tanto em regiões desenvolvidas quanto emergentes.

Dinâmica do mercado de testes no local de atendimento (POCT) na América do Norte

Motorista

“Crescente demanda por soluções de diagnóstico rápidas, descentralizadas e centradas no paciente”

Um fator importante que impulsiona o crescimento do mercado de testes no local de atendimento (POCT) na América do Norte é a crescente necessidade de ferramentas de diagnóstico rápidas, acessíveis e descentralizadas que aprimorem a tomada de decisões clínicas e os resultados para os pacientes. À medida que os sistemas de saúde se voltam para modelos baseados em valor e centrados no paciente, o POCT oferece resultados de testes imediatos no local de atendimento ou próximo a ele, reduzindo a dependência de laboratórios centralizados e possibilitando o diagnóstico precoce e intervenções terapêuticas oportunas.
Empresas líderes do setor, como Abbott, Roche, Siemens Healthineers e Danaher, estão expandindo ativamente seus investimentos em P&D para desenvolver dispositivos POCT portáteis, altamente precisos e conectados digitalmente, capazes de oferecer diagnósticos em tempo real em hospitais, clínicas, serviços de emergência e ambientes de atendimento domiciliar. Essas inovações estão alinhadas à crescente demanda por soluções integradas de saúde digital, expansão da telemedicina e interpretação de resultados com auxílio de inteligência artificial.
Na gestão de doenças crônicas, os dispositivos POCT para monitoramento de glicose, biomarcadores cardíacos, testes de coagulação e avaliação renal estão experimentando um rápido crescimento devido à crescente prevalência de diabetes, doenças cardiovasculares e distúrbios relacionados ao estilo de vida na América do Norte. Da mesma forma, os sistemas POCT para doenças infecciosas como COVID-19, influenza, sepse, malária e HIV estão se tornando ferramentas essenciais para o controle de surtos, especialmente em regiões com recursos limitados.
O crescente foco no monitoramento remoto e domiciliar de pacientes também está impulsionando a adoção, apoiado pelo desenvolvimento de diagnósticos habilitados para smartphones, soluções de teste em dispositivos vestíveis, plataformas baseadas em nuvem e recursos de emissão de relatórios remotos que aprimoram a conectividade clínica e a continuidade do atendimento.
Com a modernização da infraestrutura de saúde, a crescente ênfase na rapidez dos diagnósticos e os fortes investimentos públicos e privados, os testes no local de atendimento (POCT, na sigla em inglês) estão se consolidando como um componente essencial para o futuro da assistência médica. À medida que a eficiência e a acessibilidade se tornam centrais para a reforma da saúde na América do Norte, espera-se que a demanda por sistemas de POCT inovadores, precisos e centrados no paciente aumente significativamente.

Restrição/Desafio

“ Custos elevados, complexidades regulatórias e preocupações com precisão e padronização ”

Apesar do forte crescimento do mercado, o mercado de testes Point-Of-Care (POCT) na América do Norte enfrenta desafios consideráveis relacionados aos altos custos de equipamentos e testes, aos rigorosos processos de aprovação regulatória e à variabilidade na precisão diagnóstica entre diferentes plataformas de dispositivos. Garantir um desempenho analítico consistente, comparável aos padrões de laboratórios centralizados, continua sendo uma barreira fundamental, principalmente à medida que o POCT se expande para os segmentos de cuidados intensivos e testes de alta complexidade.
A obtenção de aprovações de órgãos reguladores como o FDA, a EMA e outras autoridades nacionais exige ampla validação clínica, conformidade com os padrões de qualidade e vigilância pós-comercialização. Esses processos podem atrasar significativamente os cronogramas de lançamento de produtos e aumentar os custos de desenvolvimento para os fabricantes, especialmente em tecnologias de diagnóstico emergentes, como testes moleculares no ponto de atendimento (POCT) e testes multiplex.
As restrições de custos também limitam a adoção em regiões em desenvolvimento, onde orçamentos de saúde limitados e sistemas de reembolso inadequados restringem a implementação em larga escala. Além disso, desafios operacionais, como requisitos de manutenção, necessidades de treinamento de usuários e integração de fluxos de trabalho, podem dificultar a implementação em grande escala em hospitais e centros de diagnóstico.
Preocupações com relação à precisão, confiabilidade e padronização dos resultados — particularmente em testes de alta sensibilidade para doenças infecciosas e marcadores cardíacos — podem gerar hesitação entre os médicos e aumentar a dependência de testes confirmatórios centralizados. Questões relacionadas à integração de dados e à segurança cibernética em plataformas digitais de testes no ponto de atendimento também exigem estruturas tecnológicas aprimoradas e investimentos.
À medida que a tecnologia POCT evolui, a superação desses desafios financeiros, regulatórios e técnicos exigirá amplo financiamento em P&D, melhor harmonização dos padrões de diagnóstico na América do Norte e colaboração estratégica entre fabricantes de dispositivos, profissionais de saúde e agências governamentais de saúde. Até lá, essas barreiras podem continuar a limitar o ritmo de adoção em certos segmentos de mercado e regiões.

Escopo do mercado de testes no local de atendimento (POCT) na América do Norte

O mercado está segmentado com base no tipo de produto, plataforma, aplicação, modo de prescrição, usuário final e canal de distribuição.

Por tipo de produto

Com base no tipo de produto, o mercado de testes Point-of-Care (POCT) da América do Norte é segmentado em produtos para monitoramento de glicose, produtos para testes de doenças infecciosas, produtos para monitoramento cardiometabólico, produtos para testes de gravidez e fertilidade, produtos para testes hematológicos, produtos para monitoramento de coagulação, produtos para testes de drogas de abuso (DOA), produtos para testes de urina, produtos para testes de colesterol, produtos para testes de marcadores tumorais/cancerígenos, produtos para testes de sangue oculto nas fezes e outros. O segmento de produtos para monitoramento de glicose deverá dominar a maior participação de mercado em receita, com 38,86% em 2026, impulsionado pelo crescente número de casos de diabetes na América do Norte, pela demanda cada vez maior por automonitoramento domiciliar e pelos avanços tecnológicos contínuos em glicosímetros e plataformas digitais de saúde conectadas.

Por plataforma

Com base na plataforma, o mercado de testes Point-Of-Care (POCT) da América do Norte é segmentado em Ensaios de Fluxo Lateral/Testes de Imunocromatografia, Imunoensaios, Testes de Imersão, Diagnóstico Molecular, Ensaios de Química Clínica, Microfluídica, Hematologia e Outros. Espera-se que os Ensaios de Fluxo Lateral/Testes de Imunocromatografia dominem o mercado em 2026, impulsionados por sua ampla adoção na triagem de doenças infecciosas, facilidade de uso, rapidez na obtenção de resultados, baixo custo e uso extensivo durante surtos como COVID-19, influenza, malária e dengue. Sua adequação a ambientes de saúde descentralizados e remotos fortalece ainda mais o crescimento do segmento.

Por meio de aplicação

Com base na aplicação, o mercado de testes Point-Of-Care (POCT) na América do Norte é segmentado em glicemia, doenças infecciosas, monitoramento de sinais vitais, monitoramento cardíaco, coagulação, hematologia, monitoramento não invasivo de SpO2, transfusão de sangue, monitoramento não invasivo de PCO2, análise de sangue total e outros. Espera-se que a glicemia domine o mercado com a maior participação em receita em 2026, impulsionada pela crescente prevalência de diabetes, pela preferência cada vez maior dos pacientes por dispositivos portáteis de monitoramento e pela disponibilidade de glicosímetros altamente precisos e fáceis de usar, além de tecnologias de monitoramento contínuo de glicose (MCG) que auxiliam no controle do diabetes em tempo real.

Por meio de prescrição médica

Com base no Modo de Prescrição, o mercado de testes no local de atendimento (POCT) na América do Norte é segmentado em testes de venda livre (OTC) e testes com prescrição. O segmento de testes OTC representou a maior participação na receita de mercado em 2026, devido à crescente preferência do consumidor por soluções de autoteste, à disponibilidade cada vez maior de kits de diagnóstico rápido e ao foco crescente em cuidados preventivos de saúde. Os dispositivos POCT de venda livre permitem que os indivíduos monitorem parâmetros de saúde, como níveis de glicose, gravidez, fertilidade, doenças infecciosas e indicadores cardiovasculares, sem supervisão clínica.

Por usuário final

Com base no usuário final, o mercado de testes no local de atendimento (POCT) na América do Norte é segmentado em hospitais, atendimento domiciliar, clínicas, laboratórios, centros de diagnóstico, laboratórios de patologia, centros cirúrgicos ambulatoriais, centros de atendimento a idosos e outros. O segmento de hospitais representou a maior participação na receita do mercado em 2026, impulsionado pela alta demanda por testes diagnósticos rápidos para dar suporte ao atendimento de emergência, cuidados intensivos e avaliações clínicas de rotina. Dispositivos POCT — como medidores de glicose no sangue, analisadores de marcadores cardíacos, testes rápidos para doenças infecciosas, monitores de coagulação e analisadores de gases sanguíneos — são cada vez mais utilizados em ambientes hospitalares para permitir uma tomada de decisão clínica mais rápida, reduzir o tempo de espera do paciente e melhorar a eficiência do fluxo de trabalho.

Por canal de distribuição

Com base no canal de distribuição, o mercado de testes no local de atendimento (POCT) na América do Norte é segmentado em Licitação Direta, Vendas no Varejo, Vendas Online e Outros. O segmento de Licitação Direta representou a maior participação na receita do mercado em 2026, impulsionado pela aquisição em grande volume de dispositivos POCT por hospitais, laboratórios de diagnóstico e agências de saúde pública. Licitações em larga escala garantem o fornecimento consistente de ferramentas de diagnóstico essenciais — como monitores de glicose, kits de teste rápido para doenças infecciosas, analisadores de biomarcadores cardíacos e dispositivos de teste de coagulação — necessárias para testes de rotina e atendimento de emergência.

Análise Regional do Mercado de Testes no Local de Atendimento (POCT) na América do Norte

A América do Norte dominou o mercado de testes rápidos no local de atendimento (POCT) com a maior participação de receita, superior a 39,83% em 2025, impulsionada pela rápida expansão da infraestrutura de saúde da região, pelo aumento da incidência de doenças crônicas e pela crescente adoção de tecnologias de diagnóstico descentralizadas. Países como Estados Unidos, Canadá e México estão testemunhando uma forte demanda por kits de diagnóstico rápido para diabetes, doenças infecciosas, doenças cardiovasculares e monitoramento domiciliar.
O crescente investimento em saúde digital, a expansão da telemedicina e as iniciativas governamentais de apoio ao diagnóstico precoce aceleram ainda mais a implementação de testes no local de atendimento (POCT). Além disso, a grande população idosa e a crescente preferência dos consumidores por testes médicos rápidos e acessíveis reforçam o crescimento do mercado em toda a região.

Análise do Mercado de Testes no Local de Atendimento (POCT) na América do Norte e EUA

Os EUA dominaram o mercado de testes rápidos no local de atendimento (POCT) na América do Norte em 2025, impulsionados por sua infraestrutura de saúde avançada, alta conscientização sobre a detecção precoce de doenças e crescente preferência por soluções de diagnóstico domiciliar. A crescente prevalência de diabetes, doenças cardíacas, doenças respiratórias e infecções continua a impulsionar a demanda por kits de teste rápido. Fortes capacidades de P&D, alta adoção de dispositivos de teste conectados e integrados a smartphones, e um ambiente regulatório maduro contribuem ainda mais para a expansão do mercado. Além disso, a mudança para diagnósticos personalizados e no local de atendimento — combinada com o aumento de clínicas de varejo e testes em farmácias — continua a fortalecer o cenário de POCT nos EUA.

Participação de mercado de testes no local de atendimento (POCT) na América do Norte

O setor de testes no local de atendimento (POCT, na sigla em inglês) é liderado principalmente por empresas consolidadas, incluindo:

Abbott Point of Care Inc. (EUA)
Sinocare Inc. (China)
F. Hoffmann-La Roche Ltda. (Suíça)
Danaher Corporation (EUA)
Hologic, Inc. (EUA)
bioMérieux SA (França)
Siemens Healthineers AG (Alemanha)
Thermo Fisher Scientific Inc. (EUA)
BD Veritor (Becton, Dickinson and Company) (EUA)
Corporação QuidelOrtho (EUA)
Bio-Rad Laboratories, Inc. (EUA)
Werfen (Espanha)
Sekisui Diagnostics (Japão)
Trividia Health, Inc. (EUA)
Nova Biomedical Corporation (EUA)
Meridian Bioscience, Inc. (EUA)
Pfizer Inc. (EUA)
Shenzhen New Industry Biomedical Engineering Co., Ltd. (China)
Corporação Sysmex (Japão)
Wondfo (Guangzhou Wondfo Biotech Co., Ltd.) (China)
QIAGEN NV (Alemanha)
Abaxis, Inc. (EUA)
Autobio Diagnostics Co., Ltd. (China)
Getein Biotech, Inc. (China)
Chembio Diagnostics, Inc. (EUA)
EKF Diagnostics Holdings plc (Reino Unido)
Trinity Biotech plc (Irlanda)
Diagnóstico PTS (EUA)
QuantuMDx Group Ltd. (Reino Unido)
Binx Health (EUA)
Xiamen Boson Biotech Co., Ltd. (China)
Accubiotech Co., Ltd. (China)
Sienco, Inc. (EUA)
Corporação LambdaGen (EUA)

Últimos desenvolvimentos no mercado de testes Point-of-Care (POCT) na América do Norte

Em maio de 2020, o teste ID NOW COVID-19 da Abbott oferece resultados rápidos e confiáveis em minutos, auxiliando no diagnóstico oportuno e reduzindo o risco de infecção. Estudos demonstram um desempenho robusto em ambientes de pronto atendimento, com sensibilidade ≥94,7% e especificidade ≥98,6%. Apesar de alguns desafios apontados em um estudo da NYU, dados do mundo real comprovam sua eficácia. Autorizado para uso emergencial pela FDA, o teste desempenha um papel crucial na detecção da COVID-19.
Em setembro de 2025, a Dongguan E-Test Technology, subsidiária da Sinocare, recebeu a aprovação 510(k) da FDA para seus Monitores de Pressão Arterial Inteligentes da Série Multi, destacando sua precisão, segurança e recursos sem fio. Os dispositivos oferecem monitoramento de nível médico, conectividade Bluetooth e alertas inteligentes, fortalecendo a estratégia de expansão da Sinocare na América do Norte e aprimorando seu ecossistema de gerenciamento de doenças crônicas em mercados internacionais, incluindo os EUA e a Europa.
Em janeiro de 2025, a Danaher Corporation firmou uma parceria de investimento com a Innovaccer Inc., uma empresa de inteligência artificial voltada para a saúde. Essa colaboração visa acelerar a adoção de diagnósticos de precisão e cuidados baseados em valor, fornecendo aos profissionais de saúde dados unificados de pacientes e análises avançadas, melhorando os resultados para os pacientes por meio de intervenções personalizadas e oportunas.
Em novembro de 2023, a Binx Health firmou uma parceria com a Fisher Healthcare para expandir a distribuição do binx io, uma plataforma molecular para diagnóstico rápido de clamídia e gonorreia, aprovada pelo FDA. Este sistema fornece resultados com qualidade de laboratório em cerca de 30 minutos, agilizando o diagnóstico e permitindo que os médicos testem e tratem os pacientes em uma única consulta, ampliando o acesso aos cuidados de saúde.

SKU-73771

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Click on image to enlarge

Painel interativo de análise de dados
Painel de análise da empresa para oportunidades de elevado potencial de crescimento
Acesso de analista de pesquisa para personalização e customização. consultas
Análise da concorrência com painel interativo
Últimas notícias, atualizações e atualizações Análise de tendências
Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência

Pedido de demonstração

Índice

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 MULTIVARIATE MODELLING

2.6 TYPE LIFELINE CURVE

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 HEALTHCARE ECONOMY

4.3.1 HEALTHCARE EXPENDITURE

4.3.2 CAPITAL EXPENDITURE

4.3.3 CAPEX TRENDS

4.3.4 CAPEX ALLOCATION

4.3.5 FUNDING SOURCES

4.3.6 INDUSTRY BENCHMARKS

4.3.7 GDP RATIO IN OVERALL GDP

4.3.8 HEALTHCARE SYSTEM STRUCTURE

4.3.9 GOVERNMENT POLICIES

4.3.10 ECONOMIC DEVELOPMENT

4.4 REIMBURSEMENT FRAMEWORK

4.5 OPPORTUNITY MAP ANALYSIS

4.6 VALUE CHAIN ANALYSIS

4.7 MICRO AND MACRO ECONOMIC FACTORS

4.7.1 CURRENT MARKET PENETRATION

4.7.2 GROWTH PROSPECTS

4.7.3 KEY PRICING STRATEGIES

4.8 TECHNOLOGY ROADMAP: NORTH AMERICA POINT OF CARE TESTING

5 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING USE OF POC TESTING IN HEALTHCARE FACILITIES

6.1.2 RISING INCIDENCE OF SUBSTANCE ABUSE

6.1.3 INCREASED ADOPTION OF TELEMEDICINE

6.1.4 ADVANCEMENTS TECHNOLOGIES ENHANCING POC TESTING WITH BIOSENSORS AND MOBILE INTEGRATION

6.2 RESTRAINTS

6.2.1 DATA SECURITY AND PRIVACY CONCERNS

6.2.2 LACK OF ACCURACY AND TECHNICAL CHALLENGES

6.3 OPPORTUNITIES

6.3.1 RISING AWARENESS AND ADVOCACY FOR POINT-OF-CARE TESTING

6.3.2 STRATEGIC INITIATION AND DECISION TAKEN BY THE MARKET PLAYERS

6.3.3 EXPANDING PRODUCT RANGE FOR POINT-OF-CARE TESTING

6.4 CHALLENGES

6.4.1 LIMITED AWARENESS AND ACCEPTANCE

6.4.2 IMPACT OF HIGH MAINTENANCE COSTS THREATENING POINT-OF-CARE TESTING (POCT) SUSTAINABILITY IN LOW-RESOURCE SETTINGS

7 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 GLUCOSE MONITORING PRODUCTS

7.2.1 SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES

7.2.1.1 Strips

7.2.1.2 Meters

7.2.1.3 Lancets and Lancing Devices

7.2.2 CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEMS

7.3 INFECTIOUS DISEASE TESTING PRODUCTS

7.3.1 COVID-19

7.3.2 HIV TESTING PRODUCTS

7.3.2.1 Testing Reagents

7.3.2.2 Testing Equipment

7.3.3 RESPIRATORY INFECTION TESTING PRODUCTS

7.3.4 SEXUALLY TRANSMITTED DISEASES (STD) TESTING

7.3.4.1 NAAT-Based Systems

7.3.4.2 NON–NAAT-Based Systems

7.3.5 HEPATITIS C TESTING PRODUCTS

7.3.5.1 HCV Antibody Tests

7.3.5.2 HCV Viral Load Tests

7.3.6 INFLUENZA TESTING PRODUCTS

7.3.6.1 Traditional Diagnostic Test

7.3.6.2 Molecular Diagnostic Assay

7.3.6.2.1 Rapid Influenza Diagnostic Test (RIDT)

7.3.6.2.2 Direct Fluorescent Antibody Test (DFAT)

7.3.6.2.3 Viral Culture

7.3.6.2.4 Serological Assay

7.3.6.3 RT-PCR

7.3.6.4 Loop-Mediated Isothermal Amplification-Based Assay (LAMP)

7.3.6.5 Nucleic Acid Sequence-Based Amplification Test (NASBAT)

7.3.6.6 Simple Amplification-Based Assay (SAMBA)

7.3.6.7 Healthcare Associated Infection (HAI) Testing

7.3.6.8 Tropical Disease Testing Products

7.3.6.9 Other Infectious Disease Testing Products

7.4 CARDIOMETABOLIC MONITORING PRODUCTS

7.4.1 CARDIAC MARKER TESTING PRODUCTS

7.4.1.1 HSTNL

7.4.1.2 BNP

7.4.1.3 D-DIMER

7.4.1.4 CK-MB

7.4.1.5 Myoglobin

7.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS

7.4.2.1 Blood Gas/Electrolyte Testing Consumables

7.4.2.2 Blood Gas/Electrolyte Testing Instruments

7.4.3 CARTRIDGES

7.4.4 REAGENTS

7.4.4.1 Portable

7.4.4.2 Benchtop

7.4.4.3 Combined Analyzers

7.4.4.4 Blood Gas Analyzers

7.4.4.5 Electrolyte Analyzers

7.4.4.6 Combined Analyzers

7.4.4.7 Blood Gas Analyzers

7.4.4.8 Electrolyte Analyzers

7.4.5 HBA1C TESTING PRODUCTS

7.4.5.1 HBA1C Testing Instruments

7.4.5.2 HBA1C Testing Consumables

7.4.5.3 POC Analyzer

7.4.5.4 ECG Device

7.4.5.5 Resting ECG Devices

7.4.5.6 Stress ECG Devices

7.4.5.7 Holter Monitors

7.5 PREGNANCY AND FERTILITY TESTING PRODUCTS

7.5.1 PREGNANCY TESTING PRODUCTS

7.5.1.1 Strips/ Dip Sticks and Cards

7.5.1.2 Mid Stream Devices

7.5.1.3 Cassettes

7.5.1.4 Digital Devices

7.5.1.5 Line-Indicator Devices

7.5.2 FERTILITY TESTING PRODUCTS

7.5.2.1 Luteinizing Hormone (LH) Urine Test

7.5.2.2 FSH Test

7.5.2.3 others

7.6 HAEMATOLOGY TESTING PRODUCTS

7.7 COAGULATION MONITORING PRODUCTS

7.7.1 ANTICOAGULATION MONITORING DEVICES

7.7.1.1 Prothrombin Time/International Normalized Ratio (PT-INR) Testing Devices

7.7.1.2 Activated Clotting Time (ACT)

7.7.1.3 Activated Partial Thromboplastin Time (APPT)

7.7.1.4 Platelet Function Monitoring Devices

7.7.1.5 Viscoelastic Coagulation Monitoring Devices

7.7.1.6 Rotational Thromboelastometry (ROTEM)

7.7.1.7 Thromboelastography (TEG)

7.7.1.8 Drug-Of-Abuse (DOA) Testing Products

7.7.2 DOA ANALYSERS

7.7.2.1 Immunoassays

7.7.2.2 Chromatographic Devices

7.7.2.3 Breath Analysers

7.7.3 RAPID TESTING DEVICES

7.7.3.1 Urine Testing Devices

7.7.3.2 Oral Fluid Testing Devices

7.7.3.4 Others

7.8 URINALYSIS TESTING PRODUCTS

7.8.1.1 POC Urine Strip Self-Testing

7.8.1.2 POC Urine Test Strip Professional Testing

7.9 CHOLESTEROL TESTING PRODUCTS

7.9.1.1 Testing Kits

7.9.1.2 Instruments

7.9.1.3 Table-Top Analyzers

7.9.1.4 Hand-Held Analyzers

7.1 TUMOR/CANCER MARKER TESTING PRODUCTS

7.11 FECAL OCCULT TESTING PRODUCTS

7.11.1.1 Guaiac FOB Stool Test

7.11.1.2 Lateral Flow Immuno-FOB Test

7.11.1.3 Immuno-FOB Agglutination Test

7.11.1.4 Immuno-FOB ELISA Test

7.12 OTHERS

8 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET, BY PLATFORM

8.1 OVERVIEW

8.2 LATERAL FLOW ASSAYS/IMMUNOCHROMATOGRAPHY TESTS

8.3 IMMUNOASSAYS

8.4 DIPSTICKS

8.5 MOLECULAR DIAGNOSTICS

8.6 CLINICAL CHEMISTRY ASSAYS

8.7 MICROFLUIDICS

8.8 HEMATOLOGY

8.9 OTHERS

9 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 BLOOD GLUCOSE

9.3 INFECTIOUS DISEASES

9.3.1 COVID-19 TESTING

9.3.2 HIV TESTING

9.3.3 HEPATITIS C TESTING

9.3.4 INFLUENZA TESTING

9.3.5 TUBERCULOSIS TESTING

9.3.6 OTHERS

9.4 VITAL SIGN MONITORING

9.5 CARDIAC MONITORING

9.6 COAGULATION

9.7 HAEMATOLOGY

9.8 NON- INVASIVE SPO2 MONITORING

9.9 BLOOD TRANSFUSION

9.1 NON- INVASIVE PCO2 MONITORING

9.11 WHOLE BLOOD ANALYSIS

9.12 OTHERS

10 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET, BY PRESCRIPTION MODE

10.1 OVERVIEW

10.2 OTC TESTING

10.3 PRESCRIPTION-BASED TESTING

11 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TENDER

11.3 RETAIL SALES

11.4 ONLINE SALES

11.5 OTHERS

12 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET, BY END USER

12.1 OVERVIEW

12.2 HOSPITALS

12.2.1 PRIVATE

12.2.1.1 Tier 1

12.2.1.2 Tier 2

12.2.1.3 Tier 3

12.2.2 PUBLIC

12.2.2.1 Tier 1

12.2.2.2 Tier 2

12.2.2.3 Tier 3

12.3 HOME CARE

12.4 CLINICS

12.5 LABORATORIES

12.6 DIAGNOSTIC CENTERS

12.7 PATHOLOGY LABS

12.8 AMBULATORY SURGERY CENTERS

12.9 ELDERLY CARE CENTERS

12.1 OTHERS

13 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION

13.1 NORTH AMERICA

13.1.1 U.S.

13.1.2 CANADA

13.1.3 MEXICO

14 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: GLOBAL

15 SWOT ANALYSIS

16 COMPANY PROFILES

16.1 ABBOTT POINT OF CARE INC(ABBOTT)

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENT

16.2 SINOCARE.

16.2.1 COMPANY SNAPSHOT

16.2.2 COMPANY SHARE ANALYSIS

16.2.3 PRODUCT PORTFOLIO

16.2.4 RECENT DEVELOPMENT

16.3 F. HOFFMANN-LA ROCHE LTD

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENT

16.4 DANAHER

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENT

16.5 HOLOGIC, INC

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENT

16.6 ACCUBIOTECH CO., LTD.

16.6.1 COMPANY SNAPSHOT

16.6.2 PRODUCT PORTFOLIO

16.6.3 RECENT DEVELOPMENT

16.7 ABAXIS (ABAXIS IS A PART OF ZOETIS)

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENT

16.8 AUTOBIO

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENT

16.9 BD VERITOR(BD)

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENT

16.1 BINX HEALTH

16.10.1 COMPANY SNAPSHOT

16.10.2 SOLUTION PORTFOLIO

16.10.3 RECENT DEVELOPMENT

16.11 BIOMERIEUX

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 BIO- RAD LABORATORIES, INC.

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 CHEMBIO DIAGNOSTICS, INC.

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENT

16.14 EKF DIAGNOSTICS HOLDINGS PLC

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENT

16.15 GETEIN BIOTECH, INC.

16.15.1 COMPANY SNAPSHOT

16.15.2 REVENUE ANALYSIS

16.15.3 PRODUCT PORTFOLIO

16.15.4 RECENT DEVELOPMENT

16.16 LAMDAGEN CORPORATION

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENT

16.17 MERIDIAN BIOSCIENCE

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENT

16.18 NOVA BIOMEDICAL

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENT

16.19 PFIZER INC.

16.19.1 COMPANY SNAPSHOT

16.19.2 PRODUCT PORTFOLIO

16.19.3 RECENT DEVELOPMENT

16.2 PTS DIAGNOSTICS

16.20.1 COMPANY SNAPSHOT

16.20.2 PRODUCT PORTFOLIO

16.20.3 RECENT DEVELOPMENT

16.21 QIAGEN

16.21.1 COMPANY SNAPSHOT

16.21.2 REVENUE ANALYSIS

16.21.3 PRODUCT PORTFOLIO

16.21.4 RECENT DEVELOPMENT

16.22 QUIDELORTHO CORPORATION

16.22.1 COMPANY SNAPSHOT

16.22.2 REVENUE ANALYSIS

16.22.3 PRODUCT PORTFOLIO

16.22.4 RECENT DEVELOPMENT

16.23 QUANTUMDX GROUP LTD.

16.23.1 COMPANY SNAPSHOT

16.23.2 PRODUCT PORTFOLIO

16.23.3 RECENT DEVELOPMENT

16.24 SEKISUI DIAGNOSTICS

16.24.1 COMPANY SNAPSHOT

16.24.2 PRODUCT PORTFOLIO

16.24.3 RECENT. DEVELOPMENT

16.25 SHENZHEN NEW INDUSTRY BIOMEDICAL ENGINEERING CO., LTD.

16.25.1 COMPANY SNAPSHOT

16.25.2 REVENUE ANALYSIS

16.25.3 PRODUCT PORTFOLIO

16.25.4 RECENT DEVELOPMENT

16.26 SIEMENS HEALTHINEERS AG

16.26.1 COMPANY SNAPSHOT

16.26.2 REVENUE ANALYSIS

16.26.3 PRODUCT PORTFOLIO

16.26.4 RECENT DEVELOPMENT

16.27 SIENCO, INC.

16.27.1 COMPANY SNAPSHOT

16.27.2 PRODUCT PORTFOLIO

16.27.3 RECENT UPDATES

16.28 SYSMEX CORPORATION

16.28.1 COMPANY SNAPSHOT

16.28.2 REVENUE ANALYSIS

16.28.3 PRODUCT PORTFOLIO

16.28.4 RECENT DEVELOPMENT

16.29 TRINITY BIOTECH

16.29.1 COMPANY SNAPSHOT

16.29.2 REVENUE ANALYSIS

16.29.3 PR.ODUCT PORTFOLIO

16.29.4 RECENT DEVELOPMENT

16.3 TRIVIDIA HEALTH, INC.

16.30.1 COMPANY SNAPSHOT

16.30.2 PRODUCT PORTFOLIO

16.30.3 RECENT UPDATES

16.31 THERMO FISHER SCIENTIFIC INC.

16.31.1 COMPANY SNAPSHOT

16.31.2 REVENUE ANALYSIS

16.31.3 PRODUCT PORTFOLIO

16.31.4 RECENT DEVELOPMENT

16.32 WERFEN

16.32.1 COMPANY SNAPSHOT

16.32.2 PRODUCT PORTFOLIO

16.32.3 RECENT DEVELOPMENT

16.33 WONDFO

16.33.1 COMPANY SNAPSHOT

16.33.2 REVENUE ANALYSIS

16.33.3 PRODUCT PORTFOLIO

16.33.4 RECENT DEVELOPMENT

16.34 XIAMEN BOSON BIOTECH CO., LTD.

16.34.1 COMPANY SNAPSHOT

16.34.2 PRODUCT PORTFOLIO

16.34.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

Lista de Tabela

TABLE 1 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 2 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 3 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 4 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 5 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 6 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 7 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 8 NORTH AMERICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 9 NORTH AMERICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 10 NORTH AMERICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 11 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 12 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)

TABLE 13 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSANDS UNITS)

TABLE 14 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 15 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 16 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 17 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 18 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 19 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 20 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 21 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)

TABLE 22 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 23 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 24 NORTH AMERICA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 25 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 26 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 27 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 28 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 29 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 30 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 31 NORTH AMERICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 32 NORTH AMERICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 33 NORTH AMERICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 34 NORTH AMERICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 35 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 36 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 37 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 38 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 39 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 40 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 41 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 42 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 43 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 44 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 45 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 46 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)

TABLE 47 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 48 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 49 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 50 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 51 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 52 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 53 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 54 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 55 NORTH AMERICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 56 NORTH AMERICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 57 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 58 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSANDS UNITS)

TABLE 59 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 60 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 61 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 62 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 63 NORTH AMERICA HAEMATOLOGY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 64 NORTH AMERICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)

TABLE 65 NORTH AMERICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)

TABLE 66 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 67 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 68 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 69 NORTH AMERICA VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSANDS)

TABLE 70 NORTH AMERICA DRUGS-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 71 NORTH AMERICA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 72 NORTH AMERICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)

TABLE 73 NORTH AMERICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 74 NORTH AMERICA DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 75 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 76 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 77 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 78 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 79 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 80 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 81 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 82 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 83 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 84 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSANDS UNITS)

TABLE 85 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 86 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSANDS)

TABLE 87 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 88 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 89 NORTH AMERICA TUMOR/CANCER MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 90 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 91 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 92 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSANDS UNITS)

TABLE 93 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 94 NORTH AMERICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 95 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)

TABLE 96 NORTH AMERICA LATERAL FLOW ASSAYS/IMMUNOCHROMATOGRAPHY TESTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)

TABLE 97 NORTH AMERICA IMMUNOASSAYS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)

TABLE 98 NORTH AMERICA DIPSTICKS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)

TABLE 99 NORTH AMERICA MOLECULAR DIAGNOSTICS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)

TABLE 100 NORTH AMERICA CLINICAL CHEMISTRY ASSAYS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 101 NORTH AMERICA MICROFLUIDICS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)

TABLE 102 NORTH AMERICA HEMATOLOGY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)

TABLE 103 NORTH AMERICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)

TABLE 104 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 105 NORTH AMERICA BLOOD GLUCOSE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 106 NORTH AMERICA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 107 NORTH AMERICA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 108 NORTH AMERICA VITAL SIGN MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 109 NORTH AMERICA CARDIAC MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 110 NORTH AMERICA COAGULATION IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 111 NORTH AMERICA HAEMATOLOGY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 112 NORTH AMERICA NON-INVASIVE SPO2 MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 113 NORTH AMERICA BLOOD TRANSFUSION IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 114 NORTH AMERICA NON-INVASIVE PCO2 MONITORING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 115 NORTH AMERICA WHOLE BLOOD ANALYSIS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 116 NORTH AMERICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 117 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSANDS)

TABLE 118 NORTH AMERICA OTC TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSAND)

TABLE 119 NORTH AMERICA PRESCRIPTION-BASED TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD THOUSANDS)

TABLE 120 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD MILLION)

TABLE 121 NORTH AMERICA DIRECT TENDER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD MILLIONS)

TABLE 122 NORTH AMERICA RETAIL SALES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD MILLIONS)

TABLE 123 NORTH AMERICA ONLINE SALES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD MILLIONS)

TABLE 124 NORTH AMERICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2033 (USD MILLIONS)

TABLE 125 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 126 NORTH AMERICA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSANDS)

TABLE 127 NORTH AMERICA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2032 (USD THOUSANDS)

TABLE 128 NORTH AMERICA PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSANDS)

TABLE 129 NORTH AMERICA PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2032 (USD THOUSANDS)

TABLE 130 NORTH AMERICA HOME CARE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 131 NORTH AMERICA CLINICS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 132 NORTH AMERICA LABORATORIES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 133 NORTH AMERICA DIAGNOSTIC CENTERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 134 NORTH AMERICA PATHOLOGY LABS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 135 NORTH AMERICA AMBULATORY SURGERY CENTERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 136 NORTH AMERICA ELDERLY CARE CENTERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 137 NORTH AMERICA OTHERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 138 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)

TABLE 139 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)

TABLE 140 NORTH AMERICA

TABLE 141 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 142 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 143 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 144 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 145 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 146 NORTH AMERICA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 147 NORTH AMERICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 148 NORTH AMERICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 149 NORTH AMERICA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 150 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 151 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 152 NORTH AMERICA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 153 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 154 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 155 NORTH AMERICA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 156 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 157 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 158 NORTH AMERICA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 159 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 160 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 161 NORTH AMERICA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 162 NORTH AMERICA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 163 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 164 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 165 NORTH AMERICA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 166 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 167 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 168 NORTH AMERICA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 169 NORTH AMERICA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 170 NORTH AMERICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 171 NORTH AMERICA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 172 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 173 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 174 NORTH AMERICA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 175 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 176 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 177 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 178 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 179 NORTH AMERICA BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 180 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 181 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 182 NORTH AMERICA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 183 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 184 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 185 NORTH AMERICA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 186 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 187 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 188 NORTH AMERICA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 189 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 190 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 191 NORTH AMERICA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 192 NORTH AMERICA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 193 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 194 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 195 NORTH AMERICA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 196 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 197 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 198 NORTH AMERICA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 199 NORTH AMERICA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 200 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 201 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 202 NORTH AMERICA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 203 NORTH AMERICA VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSAND)

TABLE 204 NORTH AMERICA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 205 NORTH AMERICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 206 NORTH AMERICA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 207 NORTH AMERICA DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 208 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 209 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 210 NORTH AMERICA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 211 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 212 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 213 NORTH AMERICA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 214 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 215 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 216 NORTH AMERICA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 217 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 218 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 219 NORTH AMERICA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 220 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 221 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 222 NORTH AMERICA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 223 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)

TABLE 224 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 225 NORTH AMERICA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 226 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSAND)

TABLE 227 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 228 NORTH AMERICA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 229 NORTH AMERICA PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)

TABLE 230 NORTH AMERICA PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)

TABLE 231 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 232 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 233 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 234 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 235 U.S. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 236 U.S. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 237 U.S. GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 238 U.S. SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 239 U.S. SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 240 U.S. SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 241 U.S. INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 242 U.S. INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 243 U.S. INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 244 U.S. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 245 U.S. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 246 U.S. HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 247 U.S. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 248 U.S. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 249 U.S. SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 250 U.S. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 251 U.S. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 252 U.S. HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 253 U.S. INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 254 U.S. TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 255 U.S. TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 256 U.S. TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 257 U.S. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 258 U.S. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 259 U.S. MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 260 U.S. CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 261 U.S. POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 262 U.S. POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 263 U.S. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 264 U.S. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 265 U.S. CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 266 U.S. BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 267 U.S. BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 268 U.S. BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 269 U.S. BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 270 U.S. BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 271 U.S. PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 272 U.S. PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 273 U.S. PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 274 U.S. BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 275 U.S. BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 276 U.S. BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 277 U.S. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 278 U.S. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 279 U.S. HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 280 U.S. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 281 U.S. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 282 U.S. ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 283 U.S. PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 284 U.S. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 285 U.S. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 286 U.S. PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 287 U.S. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 288 U.S. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 289 U.S. FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 290 U.S. COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 291 U.S. ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 292 U.S. ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 293 U.S. ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 294 U.S. VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSAND)

TABLE 295 U.S. DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 296 U.S. DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 297 U.S. DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 298 U.S. DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 299 U.S. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 300 U.S. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 301 U.S. RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 302 U.S. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 303 U.S. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 304 U.S. URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 305 U.S. CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 306 U.S. CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 307 U.S. CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 308 U.S. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 309 U.S. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 310 U.S. INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 311 U.S. FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 312 U.S. FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 313 U.S. FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 314 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)

TABLE 315 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 316 U.S. INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 317 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSAND)

TABLE 318 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 319 U.S. HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 320 U.S. PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)

TABLE 321 U.S. PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)

TABLE 322 U.S. POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 323 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 324 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 325 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 326 CANADA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 327 CANADA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 328 CANADA GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 329 CANADA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 330 CANADA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 331 CANADA SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 332 CANADA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 333 CANADA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 334 CANADA INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 335 CANADA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 336 CANADA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 337 CANADA HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 338 CANADA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 339 CANADA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 340 CANADA SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 341 CANADA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 342 CANADA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 343 CANADA HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 344 CANADA INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 345 CANADA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 346 CANADA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 347 CANADA TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 348 CANADA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 349 CANADA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 350 CANADA MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 351 CANADA CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 352 CANADA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 353 CANADA POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 354 CANADA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 355 CANADA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 356 CANADA CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 357 CANADA BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 358 CANADA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 359 CANADA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 360 CANADA BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 361 CANADA BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 362 CANADA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 363 CANADA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 364 CANADA PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 365 CANADA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 366 CANADA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 367 CANADA BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 368 CANADA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 369 CANADA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 370 CANADA HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 371 CANADA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 372 CANADA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 373 CANADA ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 374 CANADA PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 375 CANADA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 376 CANADA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 377 CANADA PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 378 CANADA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 379 CANADA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 380 CANADA FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 381 CANADA COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 382 CANADA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 383 CANADA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 384 CANADA ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 385 CANADA VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSAND)

TABLE 386 CANADA DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 387 CANADA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 388 CANADA DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 389 CANADA DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 390 CANADA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 391 CANADA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 392 CANADA RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 393 CANADA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 394 CANADA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 395 CANADA URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 396 CANADA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 397 CANADA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 398 CANADA CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 399 CANADA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 400 CANADA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 401 CANADA INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 402 CANADA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 403 CANADA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 404 CANADA FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 405 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)

TABLE 406 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 407 CANADA INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 408 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSAND)

TABLE 409 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 410 CANADA HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 411 CANADA PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)

TABLE 412 CANADA PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)

TABLE 413 CANADA POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

TABLE 414 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 415 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 416 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 417 MEXICO GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 418 MEXICO GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 419 MEXICO GLUCOSE MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 420 MEXICO SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 421 MEXICO SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 422 MEXICO SELF-MONITORING OF BLOOD GLUCOSE (SMBG) DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 423 MEXICO INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 424 MEXICO INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 425 MEXICO INFECTIOUS DISEASE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 426 MEXICO HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 427 MEXICO HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 428 MEXICO HIV TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 429 MEXICO SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 430 MEXICO SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 431 MEXICO SEXUALLY TRANSMITTED DISEASES (STD) TESTING IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 432 MEXICO HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 433 MEXICO HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 434 MEXICO HEPATITIS C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 435 MEXICO INFLUENZA TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 436 MEXICO TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 437 MEXICO TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 438 MEXICO TRADITIONAL DIAGNOSTIC TEST IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 439 MEXICO MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 440 MEXICO MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 441 MEXICO MOLECULAR DIAGNOSTIC ASSAY IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 442 MEXICO CARDIOMETABOLIC MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 443 MEXICO POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 444 MEXICO POC ANALYZER IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 445 MEXICO CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 446 MEXICO CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 447 MEXICO CARDIAC MARKER TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 448 MEXICO BLOOD GAS/ELECTROLYTE TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 449 MEXICO BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 450 MEXICO BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 451 MEXICO BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 452 MEXICO BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 453 MEXICO PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 454 MEXICO PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 455 MEXICO PORTABLE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 456 MEXICO BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 457 MEXICO BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 458 MEXICO BENCHTOP IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 459 MEXICO HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 460 MEXICO HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 461 MEXICO HBA1C TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 462 MEXICO ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 463 MEXICO ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 464 MEXICO ECG DEVICE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 465 MEXICO PREGNANCY AND FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 466 MEXICO PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 467 MEXICO PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 468 MEXICO PREGNANCY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 469 MEXICO FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 470 MEXICO FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 471 MEXICO FERTILITY TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 472 MEXICO COAGULATION MONITORING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 473 MEXICO ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 474 MEXICO ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 475 MEXICO ANTICOAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 476 MEXICO VISCOELASTIC COAGULATION MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY METHOD, 2018-2033 (USD THOUSAND)

TABLE 477 MEXICO DRUG-OF-ABUSE (DOA) TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 478 MEXICO DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 479 MEXICO DOA ANALYZERS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 480 MEXICO DOA ANALYZERS MONITORING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 481 MEXICO RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 482 MEXICO RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 483 MEXICO RAPID TESTING DEVICES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 484 MEXICO URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 485 MEXICO URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 486 MEXICO URINALYSIS TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 487 MEXICO CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 488 MEXICO CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 489 MEXICO CHOLESTEROL TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 490 MEXICO INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 491 MEXICO INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 492 MEXICO INSTRUMENTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 493 MEXICO FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (USD THOUSAND)

TABLE 494 MEXICO FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (VOLUME IN THOUSAND UNITS)

TABLE 495 MEXICO FECAL OCCULT TESTING PRODUCTS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY PRODUCT TYPE, 2018-2033 (ASP IN USD/UNITS)

TABLE 496 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY PLATFORM, 2018-2033 (USD THOUSAND)

TABLE 497 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY APPLICATION, 2018-2033 (USD THOUSAND)

TABLE 498 MEXICO INFECTIOUS DISEASES IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 499 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY PRESCRIPTION MODE, 2018-2033 (USD THOUSAND)

TABLE 500 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY END USER, 2018-2033 (USD THOUSAND)

TABLE 501 MEXICO HOSPITALS IN POINT-OF-CARE-TESTING (POCT) MARKET, BY TYPE, 2018-2033 (USD THOUSAND)

TABLE 502 MEXICO PRIVATE IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)

TABLE 503 MEXICO PUBLIC IN POINT-OF-CARE-TESTING (POCT) MARKET, BY LEVEL, 2018-2033 (USD THOUSAND)

TABLE 504 MEXICO POINT-OF-CARE-TESTING (POCT) MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)

Lista de Figura

FIGURE 1 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: DBMR MARKET POSITION GRID

FIGURE 8 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET EXECUTIVE SUMMARY

FIGURE 12 STRATEGIC DECISIONS

FIGURE 13 RISING USE OF POC TESTING IN HEALTHCARE FACILITIES IS EXPECTED TO DRIVE THE GROWTH OF NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET FROM 2026 TO 2033

FIGURE 14 THE GLUCOSE MONITORING PRODUCTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET IN 2026 - 2032

FIGURE 15 DRCO ANALYSIS

FIGURE 16 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, 2025

FIGURE 17 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, 2026-2033 (USD THOUSAND)

FIGURE 18 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, CAGR (2026-2033)

FIGURE 19 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 20 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, 2025

FIGURE 21 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, 2026 TO 2033 (USD THOUSAND)

FIGURE 22 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, CAGR (2026- 2033)

FIGURE 23 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PLATFORM, LIFELINE CURVE

FIGURE 24 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2025

FIGURE 25 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, 2026 TO 2033 (USD THOUSAND)

FIGURE 26 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, CAGR (2026- 2033)

FIGURE 27 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 28 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, 2025

FIGURE 29 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, 2026 TO 2033 (USD THOUSAND)

FIGURE 30 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, CAGR (2026- 2033)

FIGURE 31 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY PRESCRIPTION MODE, LIFELINE CURVE

FIGURE 32 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2025

FIGURE 33 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, 2026 TO 2033 (USD THOUSAND)

FIGURE 34 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2026- 2033)

FIGURE 35 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 36 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, 2025

FIGURE 37 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, 2026 TO 2033 (USD THOUSAND)

FIGURE 38 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, CAGR (2026- 2033)

FIGURE 39 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 NORTH AMERICA POINT-OF-CARE-TESTING (POCT) MARKET: SNAPSHOT

FIGURE 41 NORTH AMERICA POINT-OF-CARE TESTING (POCT) MARKET: COMPANY SHARE 2025 (%)

View Detailed Information

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

Quais são os principais segmentos abordados no relatório Relatório de Análise do Tamanho, Participação e Tendências do Mercado?

O mercado é segmentado com base em Mercado de Testes no Local de Atendimento (POCT) na América do Norte, por Tipo de Produto (Produtos para Monitoramento de Glicose, Produtos para Testes de Doenças Infecciosas, Produtos para Monitoramento Cardiometabólico, Produtos para Testes de Gravidez e Fertilidade, Produtos para Testes Hematológicos, Produtos para Monitoramento da Coagulação, Produtos para Testes de Drogas de Abuso (DOA), Produtos para Testes de Urina, Produtos para Testes de Colesterol, Produtos para Testes de Marcadores Tumorais/Cancerígenos, Produtos para Testes de Oculto Fecal e Outros), por Plataforma (Ensaios de Fluxo Lateral/Testes de Imunocromatografia, Imunoensaios, Tiras de Imersão, Diagnóstico Molecular, Ensaios de Química Clínica, Microfluídica, Hematologia e Outros), por Aplicação (Glicose no Sangue, Doenças Infecciosas, Monitoramento de Sinais Vitais, Monitoramento Cardíaco, Coagulação, Hematologia, Monitoramento Não Invasivo de SpO2, Transfusão de Sangue, Monitoramento Não Invasivo de PCO2, Análise de Sangue Total e Outros). Modalidade de prescrição (testes com prescrição e testes de venda livre), por usuário final (hospitais, assistência domiciliar, clínicas, laboratórios, centros de diagnóstico, laboratórios de patologia, centros cirúrgicos ambulatoriais, centros de cuidados para idosos e outros), por canal de distribuição (licitação direta, vendas no varejo, vendas online e outros) e por país (EUA, Canadá e México) - Tendências e previsões do setor até 2033. .

Qual é o tamanho atual do mercado de Relatório de Análise do Tamanho, Participação e Tendências do Mercado?

O tamanho do Relatório de Análise do Tamanho, Participação e Tendências do Mercado foi avaliado em USD 25.20 USD Billion no ano de 2025.

Qual é a taxa de crescimento esperada para Relatório de Análise do Tamanho, Participação e Tendências do Mercado?

O Relatório de Análise do Tamanho, Participação e Tendências do Mercado está projetado para crescer a um CAGR de 9.6% durante o período de previsão de 2026 a 2033.

Quem são os principais players do Relatório de Análise do Tamanho, Participação e Tendências do Mercado?

Os principais players do mercado incluem Abbott Point of Care Inc. ,Sinocare Inc. ,F. Hoffmann-La Roche Ltd ,Danaher Corporation ,Hologic Inc. ,bioMérieux SA.

Relatório de Análise do Tamanho, Participação e Tendências do Mercado de Testes no Local de Atendimento (POCT) na América do Norte – Visão Geral do Setor e Previsão até 2033

Contorne os desafios das tarifas com uma consultoria ágil da cadeia de abastecimento

North America Point Care Testing Poct Market

CAGR : 9.60 %

Tamanho do mercado de testes no local de atendimento (POCT) na América do Norte

Análise do mercado de testes no local de atendimento (POCT) na América do Norte

Escopo do relatório e segmentação do mercado de testes no local de atendimento (POCT) na América do Norte

Principais informações sobre o mercado de testes no local de atendimento (POCT) na América do Norte

Tendências do mercado de testes no local de atendimento (POCT) na América do Norte

Dinâmica do mercado de testes no local de atendimento (POCT) na América do Norte

Escopo do mercado de testes no local de atendimento (POCT) na América do Norte

Análise Regional do Mercado de Testes no Local de Atendimento (POCT) na América do Norte

Participação de mercado de testes no local de atendimento (POCT) na América do Norte

Últimos desenvolvimentos no mercado de testes Point-of-Care (POCT) na América do Norte

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

ISO Certifications

Relatórios

Informações de mercado

Apoiar

Soluções

Relatório de Análise do Tamanho, Participação e Tendências do Mercado de Testes no Local de Atendimento (POCT) na América do Norte – Visão Geral do Setor e Previsão até 2033

Contorne os desafios das tarifas com uma consultoria ágil da cadeia de abastecimento

North America Point Care Testing Poct Market

CAGR : 9.60 %

Tamanho do mercado de testes no local de atendimento (POCT) na América do Norte

Análise do mercado de testes no local de atendimento (POCT) na América do Norte

Escopo do relatório e segmentação do mercado de testes no local de atendimento (POCT) na América do Norte

Principais informações sobre o mercado de testes no local de atendimento (POCT) na América do Norte

Tendências do mercado de testes no local de atendimento (POCT) na América do Norte

Dinâmica do mercado de testes no local de atendimento (POCT) na América do Norte

Escopo do mercado de testes no local de atendimento (POCT) na América do Norte

Análise Regional do Mercado de Testes no Local de Atendimento (POCT) na América do Norte

Participação de mercado de testes no local de atendimento (POCT) na América do Norte

Últimos desenvolvimentos no mercado de testes Point-of-Care (POCT) na América do Norte

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

Índice

Lista de Tabela

Lista de Figura

Metodologia de Investigação

Personalização disponível

Perguntas frequentes

Navegue pelas páginas relacionadas